Method of treating hyperphosphataemia using lanthanum hydroxycarbonate
AssigneeShire Pharmaceuticals, Inc.
InventorsJosephine Ferdinando, David Gilmour
Life of this patent
Estimating the term…
Abstract
This disclosure relates to the treatment of subjects at risk for chronic kidney disease (CKD), having stage one to five CKD, having hyperphosphataemia, susceptible to or suffering from soft tissue calcification associated with CKD, or susceptible to or suffering from hyperparathyroidism, by orally administering a pharmaceutical composition containing a therapeutically effective amount of lanthanum hydroxycarbonate.
Claims9
A method of treating a subject (1) at risk for chronic kidney disease (CKD), (2) having stage one to stage five CKD, or (3) susceptible to or suffering from soft tissue calcification associated with CKD, comprising orally administering to the subject a pharmaceutical composition containing as an active ingredient a therapeutically effective amount of lanthanum hydroxycarbonate.
A method of treating hyperparathyroidism comprising administering to a patient in need thereof a therapeutically effective amount of lanthanum hydroxycarbonate.
A pharmaceutical composition comprising lanthanum hydroxycarbonate and a pharmaceutically acceptable carrier.
Dependencies are inferred from the claim text.